Details

Autor(en) / Beteiligte

• Vega, P.
• Huguet, J. M.
• Gómez, E.
• Rubio, S.
• Suarez, P.
• Vera, M. I.
• Paredes, J. M.
• Hernández-Camba, A.
• Plaza, R.
• Mañosa, M.
• Pajares, R.
• Sicilia, B.
• Madero, L.
• Kolterer, S.
• Leitner, C.
• Heatta-Speicher, T.
• Michelena, N.
• Santos de Lamadrid, R.
• Dignass, A.
• Gomollón, F.

Titel

IBD-PODCAST Spain: A Close Look at Current Daily Clinical Practice in IBD Management

Ist Teil von

• Digestive diseases and sciences, 2024-03, Vol.69 (3), p.749-765

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2024

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Background Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) that contributes in part to irreversible bowel damage and long-term complications, reduced quality of life, invalidity, and economic burden. Suboptimal control of IBD is associated with higher healthcare resource utilization (HCRU), impaired quality of life (QoL), and reduced work productivity. Aims The IBD-PODCAST study aimed to assess the proportion of IBD patients with suboptimal control and its associated impact. Methods IBD-PODCAST is a cross-sectional, multicenter study that aimed to characterize the CD and UC population with optimal or suboptimal control according to the STRIDE-II criteria and patient- and physician-reported measures. Here we present the results of the Spanish cohort ( n  = 396). Results A total of 104/196 (53.1%) CD and 83/200 (41.5%) UC patients were found to have suboptimal disease control. Long-term treatment targets according to STRIDE-II were applied in 172 (87.8%) CD and 181 (90.5%) UC patients. 125 of 172 (72.7%) CD and 74 of 181 (40.9%) UC patients were currently treated with targeted immunomodulators. Patients with CD and UC and suboptimal disease control showed impaired QoL, higher HCRU and direct costs, and also loss of work productivity compared to those with optimal control. Conclusion Despite a high rate of targeted immunomodulator therapy, a substantial proportion of IBD patients show suboptimal disease control according to the STRIDE II criteria. Those patients with suboptimal disease control exhibit impaired QoL, less work productivity, and higher HCRU, suggesting that there is considerable need for better treatment approaches in IBD.